Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07463599 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
A Phase 1 study of Colorectal Cancer (CRC) and Metastatic Colorectal Carcinoma (mCRC), sponsored by HonorHealth Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT07463599 is a Phase 1 study of Colorectal Cancer (CRC) and Metastatic Colorectal Carcinoma (mCRC) that is actively recruiting participants, run by HonorHealth Research Institute. The registered enrollment target is 126 participants, below the 395-participant average among 19 other Colorectal Cancer (CRC) trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07463599, a Phase 1 study of Colorectal Cancer (CRC) and Metastatic Colorectal Carcinoma (mCRC), is actively recruiting participants, sponsored by HonorHealth Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).
Conditions Studied
Interventions
- DRUG Tegavivint
Study Locations (1)
Arizona
- Clinical Trials Nurse Navigator - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07463599
The ClinicalTrials.gov registry entry for NCT07463599 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 395-participant average among 19 other Colorectal Cancer (CRC) trials with a reported enrollment target (68% lower). The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 1 intervention - of which Tegavivint is the first listed.
NCT07463599 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT07463599 about?
NCT07463599 is a clinical study titled "Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma". This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).
What is the current status of trial NCT07463599?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2026-02-17. Estimated completion is 2029-07.
What conditions does trial NCT07463599 study?
This clinical trial studies the following conditions: Colorectal Cancer (CRC), Metastatic Colorectal Carcinoma (mCRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation.
What interventions are being tested in trial NCT07463599?
The interventions under investigation include: Tegavivint (DRUG).
Who is sponsoring clinical trial NCT07463599?
This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07463599 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer (CRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.